Eupraxia Pharmaceuticals Appoints New Technical Operations Heads; Co-Founder Malone Steps Down

Source and reference

source on Google Add Now Eupraxia Pharmaceuticals Inc. ( EPRX ), a clinical-stage biotechnology company, announced several leadership changes within the company to support its upcoming planned phase of clinical and commercial growth. The company appointed Jeff Millard as Executive Vice President, Technical Operations, effective from July 13, 2026. Millard brings over 25 years of experience in technical operations, chemistry manufacturing and controls (CMC), and regulatory strategy to the position. He has held several senior leadership positions at Ensysce Biosciences, Inc. ( ENSC ), Microbion Corporation, and Cascadian Therapeutics. In his new role, he is expected to support the advancement and commercialization of Eupraxia's product pipeline. As part of these changes, Alex Therien, who joined the company from November 2025, has taken up the role of Executive Vice President of...